`
`Date Filed: May 19, 2017
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`________________
`
`WOCKHARDT BIO AG,
`
`Petitioner
`
`v.
`
`JANSSEN ONCOLOGY, INC.,
`Patent Owner.
`________________
`
`Case IPR2016-01582
`________________
`
`Patent No. 8,822,438 B2
`
`
`
`PATENT OWNER’S REPLY IN SUPPORT OF ITS
`MOTION TO EXCLUDE EVIDENCE
`PURSUANT TO 37 C.F.R. § 42.64(C)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2016-01582
`U.S. Patent 8,822,438
`
`Patent Owner, Janssen Oncology, Inc., submits this Reply in support of its
`
`Motion to Exclude Evidence (Paper 63 (“Mot.”)).1
`
`I.
`
`Petitioner’s Request to Ignore 35 U.S.C. § 311(b) Should Be Rejected
`
`Petitioner does not dispute that the governing statute, § 311(b), clearly and
`
`unambiguously states that petitions may seek cancellation of a claim “only on the
`
`basis of prior art consisting of patents or printed publications.” Nor does Petitioner
`
`dispute that the declaration of its economist Dr. Stoner (Ex. 1077) offers opinions
`
`on “commercial success” as part of the Petition, going beyond “patents or printed
`
`publications.” Petitioner’s arguments do not justify ignoring the statute.
`
`First, Petitioner points out that Patent Owner relied on commercial success
`
`in its Patent Owner’s Response, and that commercial success was an issue in the
`
`’438 patent prosecution history. Paper 66 at 1-2. Neither point has any bearing on
`
`the statutorily prescribed grounds for seeking cancellation in the petition, nor
`
`would Patent Owner’s Motion preclude rebuttal evidence and argument in a reply.
`
`Second, Petitioner argues that exhibits post-dating the ’438 patent should not
`
`be excluded because evidence of commercial success would be expected to post-
`
`date the ’438 patent. Paper 66 at 3. This is just an admission that the Stoner
`
`
`1 Patent Owner withdraws authentication objections to Exhibits 1050, 1077
`
`Attachment B-1, 1114, and 1116. Patent Owner objects to Petitioner’s replacement
`
`exhibits for the same reasons (Ex. 1127 replaces 1112; Ex. 1131 replaces 1070).
`
`1
`
`
`
`IPR2016-01582
`U.S. Patent 8,822,438
`
`Declaration (Ex. 1077) and associated exhibits relate to commercial success, not
`
`“prior art consisting of patents or printed publications,” in violation of § 311(b).
`
`II.
`
`Petitioner’s Uncited Evidence Is Irrelevant and Unfairly Prejudicial
`
`Petitioner does not deny that it failed to cite in its papers any of the evidence
`
`challenged on this ground, or even declarations discussing the evidence. Mot.,
`
`Paper 63 at 6-7. Evidence that is untethered from the papers should be excluded.
`
`Microsoft Corp. v. Parallel Networks Licensing, LLC, IPR2015-00485, Paper 81 at
`
`24 (Aug. 11, 2016). First Quality Baby Prods. v. Kimberly-Clark Worldwide is
`
`inapposite as it addressed a motion to exclude for failure of proof, not a failure to
`
`cite documents in the papers. IPR2014-01023, Paper 56 at 35 (Dec. 10, 2015).2
`
`Whether Petitioner can now articulate any relevance for uncited matter is
`
`immaterial as that explanation belonged in the Petition or the Reply, not at this late
`
`date shortly before the hearing. 37 C.F.R. § 42.104(b)(5). The Board should
`
`exclude Petitioner’s uncited evidence, or at a minimum give it no weight. Id.
`
`III. Petitioner Has Failed to Authenticate the Challenged Exhibits
`
`As explained in Patent Owner’s Motion, a declaration testifying to retrieving
`
`a website printout is insufficient when the website’s contents are offered as proof.
`
`
`2 Ericsson Inc. v. Intellectual Ventures II LLC, IPR2014-00915, Paper 37 at 11
`
`(Dec. 7, 2015), did not address entirely uncited exhibits. The Board should follow
`
`the more recent Microsoft decision and exclude all of Petitioner’s uncited matter.
`
`
`
`2
`
`
`
`IPR2016-01582
`U.S. Patent 8,822,438
`
`Paper 63 at 8-9. Exhibit 1034 is allegedly prior art Taxotere prescribing
`
`information. Ex. 1002 (Godley) at 9, ¶ 102. Dr. Godley’s declaration reflects only
`
`knowledge of a website printout accessed in 2016, not knowledge of the 2004
`
`contents. Ex. 1129 ¶ 4. Similarly, Exhibit 1063 is purportedly a Jevtana website,
`
`and is wrongly treated by Dr. Stoner as prior art when his declarations reflect only
`
`knowledge of a 2016 printout. Ex. 1077 ¶ 47; Ex. 1130 ¶ 10.
`
`Dr. Stoner asserts that Exhibits 1057, 1060, 1061, and 1066-1073 are “copies
`
`of investment reports” from various entities, but offers no testimony regarding how
`
`the exhibits were obtained and relies on another’s testimony from a different IPR.
`
`Ex. 1130 ¶¶ 7-8. Exhibits 1065 and 1074 are also alleged “investment reports” but
`
`Dr. Stoner’s declaration details only knowledge of website printouts. Ex. 1130 ¶¶
`
`7, 9. Exhibit 1080 is allegedly a compilation of IMS data and is summarized in
`
`Exhibit 1077 [B-2]. Dr. Stoner’s declaration provides no indication where the
`
`“compilation” in Exhibit 1080 came from, and he relies on declarations from a
`
`parallel IPR instead of his personal knowledge. Ex. 1130 ¶ 12. Exhibit 1087 is an
`
`alleged 2004 BTG press release, offered as proof of 2004 actions by BTG. Ex.
`
`1103 (Stoner) ¶ 23. Exhibit 1087 is insufficiently described by Dr. Stoner as “a
`
`document” he downloaded from a particular website in 2017. Ex. 1124 ¶¶ 4-5.
`
`Exhibit 1094 is allegedly a 2016 paper by Attard et al. Dr. Godley states, “to
`
`the best of my knowledge the exhibits cited in my initial declaration––including
`
`
`
`3
`
`
`
`IPR2016-01582
`U.S. Patent 8,822,438
`
`Exhibit[] . . . 1094––are true and accurate copies of what they purport to be . . . .”
`
`Ex. 1123 ¶ 4. But Exhibit 1094 was never cited in Dr. Godley’s initial declaration
`
`(Ex. 1002), and when addressing Exhibit 1094 specifically, Dr. Godley meekly
`
`asserts that it is “a true and correct copy of a document” he downloaded from a
`
`website in April 2017. Ex. 1123 ¶ 5 (emphasis added). Similarly, Dr. Stoner
`
`insufficiently describes each of Exhibits 1100 and 1102 as “a document” he
`
`downloaded from locations on certain websites. Ex. 1124 ¶¶ 6-7.
`
`Exhibit 1109 is purportedly a webpage regarding an abiraterone acetate
`
`clinical trial. Exhibit 1109 bears a stamp from another IPR, showing it cannot be a
`
`true copy obtained by Dr. Stoner. Ex. 1124 (Stoner) ¶ 13. Exhibit 1112 is
`
`purportedly EMA Product Information for ZYTIGA®. Ex. 1103 (Stoner) at 4,
`
`¶ 39. Dr. Stoner states that he downloaded the exhibit from another IPR and has
`
`only an “understanding” that a true and correct copy is available online. Ex. 1124
`
`¶ 15. While not obvious on its face, Exhibit 1119 is allegedly a website printout of
`
`a clinical study report, offered to prove its contents. Ex. 1106 (McKeague) ¶ 36. It
`
`is only supported by a lawyer’s description of accessing the website. Ex. 1125
`
`(Kenton) ¶ 6. None of the foregoing exhibits are authenticated.
`
`IV. Petitioner’s Hearsay Rebuttals Have No Merit
`
`Petitioner represents to the Board that all exhibits challenged for hearsay are
`
`solely offered for their effect on a person of ordinary skill, not their truth. Paper 66
`
`
`
`4
`
`
`
`IPR2016-01582
`U.S. Patent 8,822,438
`
`at 10-11. Yet Petitioner admitted that these exhibits relate to the declarations of
`
`Petitioner’s economic expert (id.), who is incompetent to make any proclamations
`
`about what a person of ordinary skill would think. If not excluded as hearsay,
`
`these exhibits should be given no weight because they are useless for their stated
`
`non-truth purpose. Petitioner also argues that Rule 703 allows disclosure of
`
`hearsay relied on by an expert, but fails to address Rule 703’s requirement that
`
`“experts in the particular field would reasonably rely on those kinds of facts or data
`
`in forming an opinion on the subject.” Petitioner thus fails to show Rule 703 is
`
`satisfied, as is required to consider inadmissible hearsay relied on by an expert.
`
`Finally, Petitioner attempts to shoehorn Exhibits 1057, 1060-1061, 1065, and
`
`1067-1073 into the market reports hearsay exception. But Rule 803(17) is
`
`intended for reliable factual documents such as newspaper stock quotes. Fed. R.
`
`Evid. 803, Notes of Advisory Committee. In contrast, these exhibits reflect the
`
`subjective views of analysts, often accompanied by warnings about conflicts of
`
`interest and reliance by the public. E.g., Ex.1057 at 1; Ex. 1060 at 2; Ex. 1061 at
`
`1, 3-4; Ex. 1065 at 8; Ex. 1067 at 1; Ex. 1068 at 1; Ex. 1069 at 1; Ex. 1071 at 1, 4,
`
`6; Ex. 1072 at 1, 5, 7; Ex. 1073 at 1; Ex. 1131 at 1 (replacement for Ex. 1070,
`
`“important disclosures” not included).
`
`V. Conclusion
`
`For the foregoing reasons, the Board should grant Patent Owner’s Motion.
`
`
`
`5
`
`
`
`IPR2016-01582
`U.S. Patent 8,822,438
`
`
`Dated: May 19, 2017
`
`Respectfully Submitted,
`
`By: /Dianne B. Elderkin/
`Dianne B. Elderkin (Reg. No. 28,598)
`delderkin@akingump.com
`Barbara L. Mullin (Reg. No. 38,250)
`bmullin@akingump.com
`Ruben H. Munoz (Reg. No. 66,998)
`rmunoz@akingump.com
`AKIN GUMP STRAUSS HAUER &
`FELD LLP
`Two Commerce Square
`2001 Market Street, Suite 4100
`Philadelphia, PA 19103
`Tel: (215) 965-1200
`Fax: (215) 965-1210
`
`David T. Pritikin (pro hac vice)
`dpritikin@sidley.com
`Bindu Donovan (pro hac vice)
`bdonovan@sidley.com
`Paul Zegger (Reg. No. 33,821)
`pzegger@sidley.com
`Todd Krause (Reg. No. 48,860)
`tkrause@sidley.com
`Alyssa B. Monsen (pro hac vice)
`amonsen@sidleyaustin.com
`SIDLEY AUSTIN LLP
`787 Seventh Avenue
`New York, NY 10019
`Tel.: (212) 839-5300
`Fax: (212) 839-5599
`ZytigaIPRTeam@sidley.com
`Counsel for Patent Owner
`
`
`
`6
`
`
`
`
`
`
`
`IPR2016-01582
`U.S. Patent 8,822,438
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing Patent
`
`Owner’s Reply in Support of Its Motion to Exclude Evidence Pursuant to 37 C.F.R.
`
`§ 42.64(c) was served on counsel of record on May 19, 2017 by filing this
`
`document through the End-to-End System, as well as delivering a copy via
`
`electronic mail to counsel of record for the Petitioner and Patent Co-Owner at the
`
`following addresses:
`
`Dennies Varughese – dvarughe-PTAB@skgf.com
`Deborah A. Sterling – dsterlin-PTAB@skgf.com
`Lestin L. Kenton Jr. – lkenton-PTAB@skgf.com
`Ralph W. Powers III – tpowers-PTAB@skgf.com
`
`Anthony C. Tridico – anthony.tridico@finnegan.com
`Jennifer H. Roscetti – jennifer.roscetti@finnegan.com
`
`
`
`
`
`
`
`Date: May 19, 2017
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`By: /Dianne B. Elderkin/
`Dianne B. Elderkin
`Registration No. 28,598
`Counsel for Patent Owner
`
`
`
`
`
`7
`
`